These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 1664831)

  • 21. Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.
    Sorgel F; Naber KG; Kinzig M; Mahr G; Muth P
    Am J Med; 1991 Dec; 91(6A):51S-66S. PubMed ID: 1662896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetration of temafloxacin into body tissues and fluids.
    Sörgel F
    Clin Pharmacokinet; 1992; 22 Suppl 1():57-63. PubMed ID: 1319872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses.
    Wise R; Honeybourne D
    J Antimicrob Chemother; 1996 May; 37 Suppl A():57-63. PubMed ID: 8737125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of quinolones with special reference to the respiratory tree.
    Decré D; Bergogne-Bérézin E
    J Antimicrob Chemother; 1993 Mar; 31(3):331-43. PubMed ID: 8486568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the pharmacokinetic profile of temafloxacin.
    Dudley MN
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():55-64. PubMed ID: 1664830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition of single-dose oral enrofloxacin in the horse.
    Langston VC; Sedrish S; Boothe DM
    J Vet Pharmacol Ther; 1996 Aug; 19(4):316-9. PubMed ID: 8866463
    [No Abstract]   [Full Text] [Related]  

  • 27. Delivering antibacterials to the lungs: considerations for optimizing outcomes.
    Cazzola M; Blasi F; Terzano C; Matera MG; Marsico SA
    Am J Respir Med; 2002; 1(4):261-72. PubMed ID: 14720046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy.
    Honeybourne D
    Curr Opin Pulm Med; 1997 Mar; 3(2):170-4. PubMed ID: 9193864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrapulmonary concentrations of antimicrobial agents.
    Nix DE
    Infect Dis Clin North Am; 1998 Sep; 12(3):631-46, viii. PubMed ID: 9779382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].
    Daniel JP; Moulin B; Christmann D
    Ann Pharm Fr; 2004 May; 62(3):177-85. PubMed ID: 15243351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of antimicrobial agents in the respiratory tract.
    Cruciani M; Gatti G; Cazzadori A; Concia E
    Zentralbl Bakteriol; 1996 Jun; 284(1):1-31. PubMed ID: 8837365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extravascular penetration of ciprofloxacin. A review.
    Bergan T
    Diagn Microbiol Infect Dis; 1990; 13(2):103-14. PubMed ID: 2196148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New concepts in the pulmonary disposition of antibiotics.
    Bergogne-Berezin E
    Pulm Pharmacol; 1995; 8(2-3):65-81. PubMed ID: 8820245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential antimicrobial therapy--the role of quinolones.
    Nathwani D; Tillotson G; Davey P
    J Antimicrob Chemother; 1997 Apr; 39(4):441-6. PubMed ID: 9145815
    [No Abstract]   [Full Text] [Related]  

  • 35. Biopharmaceutical aspects of anti-infective therapy at the extremes of age.
    Schaefer HG; Michaelis J
    J Antimicrob Chemother; 1994 Aug; 34 Suppl A():33-42. PubMed ID: 7844072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue penetration of the new quinolones in humans.
    Gerding DN; Hitt JA
    Rev Infect Dis; 1989; 11 Suppl 5():S1046-57. PubMed ID: 2672243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.
    Nikaido H; Thanassi DG
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1393-9. PubMed ID: 8363364
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens.
    MacGowan A; Rogers C; Bowker K
    J Antimicrob Chemother; 2000 Aug; 46(2):163-70. PubMed ID: 10933637
    [No Abstract]   [Full Text] [Related]  

  • 39. Pulmonary disposition of antimicrobial agents: methodological considerations.
    Baldwin DR; Honeybourne D; Wise R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1171-5. PubMed ID: 1416816
    [No Abstract]   [Full Text] [Related]  

  • 40. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.
    Baldwin DR; Honeybourne D; Wise R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1176-80. PubMed ID: 1416817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.